Introduction
Genevé Bio is developing a unique, patented treatment for erectile dysfunction that repairs and restores the tissue damaged by the underlying disease.
Our patented lead molecule is Vascular Endothelial Growth Factor (VEGF), a recombinant human protein. Unlike existing products that only address symptoms for a few hours, the Company believes that VEGF165 promotes the repair and restoration of penile tissues (endothelial, arterial, smooth muscle and neural) damaged by the underlying disease. Our ultimate goal is the reversal of erectile dysfunction potentially providing months of spontaneous, failure-free sex. It may treat those males in whom current therapies are ineffective. The Company believes that the opportunity for growth and return is therefore substantial.
Our patented lead molecule is VEGF165, a recombinant, natural protein first identified by Genentech in the 1980's. Genentech is currently conducting human trials using recombinant VEGF165 to treat diabetic foot ulcers and GenVec is using another variant of VEGF to treat angina. Their experience gives us reason to believe that administration of VEGF165 for erectile dysfunction will be safe.
VEGF165 for erectile dysfunction is novel, first-in-class, and potentially curative. Studies in rats and rabbits by different investigators suggest efficacy in reversing the damage caused by the underlying disease. After injection by a physician, we expect such repair to be effective for months, if not longer, without further treatment. No treatment is needed near the time of intercourse. The Company has exclusive options to license applicable, issued U.S. patents and corresponding patent applications in Canada, Western Europe, and Japan.
The current, world-wide market for sexual dysfunction drugs exceeds $3 billion. Nevertheless, only 15% of affected men are being treated and current treatments fail in 30-40% of these patients. Consequently, we project sales of $600 million three years after FDA approval.
The team consists of the leading researchers in sexual dysfunction and executives who've had deep experience in developing biopharmaceuticals.
We plan to exit through a strategic sale to one of the three current leaders in sexual dysfunction products after completing one or two phase II studies confirming efficacy and appropriate dosing.